4DMedical posts FY26 revenue growth as commercial deployment ramps up
4DMedical reports 21% FY26 revenue growth as CT:VQ gains commercial adoption, global regulatory approvals and major healthcare partnerships.
Market Cap $0
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Announcements
Filter Results
| REV | Operational Update | PRICE SENSITIVE | 28/02/18 | |
| REV | REV Releases Appendix 4D and Interim Financial Report | 28/02/18 | ||
| REV | Half Yearly Report and Accounts | PRICE SENSITIVE | 28/02/18 | |
| REV Operational Update | |||
| 28/02/18 | PRICE SENSITIVE | ||
| REV REV Releases Appendix 4D and Interim Financial Report | |||
| 28/02/18 | |||
| REV Half Yearly Report and Accounts | |||
| 28/02/18 | PRICE SENSITIVE | ||